Nöroleptik Malign Sendromu
Abstract
Keywords
Nöroleptik malign sendrom, ekstrapramidal fonksiyon bozukluğu, haloperidol enjeksiyonunu
References
- 1. Baldessarini RS : Drugs and the treatment of psychiatric disorders. In : Gilman AG, Goodmann LS, Rall TW, Murad F, eds. The pharmacological basis of therapeutics,7 th ed. New York, Mc Millan Pub 1985 : 387-445.
- 2. Britt BA, Kalow W : Malignant hyperthermia : A statistical review, Can Anaesth Soc J 17 : 293-315, 1970.
- 3. Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH ; Neurolepticmalignant syndrome caused by dopamine-depleting drugs in a patient withHuntington disease, Neurology (Ny) 31 : 1022 1026, 1981.
- 4,Cremona-Barbaro A : Neuroleptic induced catatonic symptoms. Br J Psyohiairy 142 : 98-99, 1988.
- 5. Daoudal P, Delacour JL : Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 2 : 217, 1982.
- 6.Dhib-Jalbut $, Hesselbrock R, Brott J, Silbergeld b : Treatment of ihe neuroleptic malignant syndrome with bromecriptine, JAMA 250 : 484-485
- 7. Fletcher JE, Rosenberg H, Lizzo FH ; Effects of droperidol, haloperidol and ketamine on halothane, succinylcholine, and caffeine contractures : implications or malignant hyperihermia. Acta Anaesthesiol Scand 33 : 187-192, 1989.
- 8. Goekop JG, Carbatt PAT : Treatment of neuroleptic malignant syndrome With danirolene. Lancet 2 ; 49-50, 1982,
- 9. Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S : Neuroleptic malignant syndrome : Succesful treatment with dantrolene and bromo-criptine, Ann Neurol 14 : 89-90, 1983.
- 10.Gronert GA : Malignant hiperthermia. Anestesiology 53 : 355-423, 1980.